Levi & Korsinsky Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 – URGN

Core Viewpoint - A class action securities lawsuit has been filed against UroGen Pharma Ltd. for alleged securities fraud affecting investors between July 27, 2023, and May 15, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that the ENVISION clinical study was inadequately designed, lacking a concurrent control arm, which undermined the evidence of effectiveness for UGN-102 [2] - It is alleged that UroGen Pharma did not heed FDA warnings regarding the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [2] - Defendants' positive statements about the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis due to the aforementioned issues [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]